These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7037038)

  • 1. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).
    Dowd PM; Martin MF; Cooke ED; Bowcock SA; Jones R; Dieppe PA; Kirby JD
    Br J Dermatol; 1982 Jan; 106(1):81-9. PubMed ID: 7037038
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of Raynaud's Syndrome with prostacyclin.
    Belch JJ; Newman P; Drury JK; Capell H; Leiberman P; James WB; Forbes CD; Prentice CR
    Thromb Haemost; 1981 Jun; 45(3):255-6. PubMed ID: 7025341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Trial treatment of severe Raynaud's phenomenon with prostacyclin (PGI2)].
    Cabane J; Boue F; Godeau P; Lecompte T; Charpentier MC; Samama M; Nebout T
    Rev Med Interne; 1985 Dec; 6(5):581-9. PubMed ID: 3914023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.
    Belch JJ; Newman P; Drury JK; McKenzie F; Capell H; Leiberman P; Forbes CD; Prentice CR
    Lancet; 1983 Feb; 1(8320):313-5. PubMed ID: 6130329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged remission in Raynaud's phenomenon after prostacyclin infusion.
    Bellucci S; Kedra AW; Courmelle JM; Maclouf J; Boizard B; Dosquet-Bernard C; Tobelem G; Caen JP
    Scand J Rheumatol; 1986; 15(4):392-8. PubMed ID: 3547631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raynaud's disease and prostacyclin.
    Kennerly D
    Ann Intern Med; 1983 Feb; 98(2):258. PubMed ID: 6337542
    [No Abstract]   [Full Text] [Related]  

  • 7. Epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome.
    Kahan A; Weber S; Amor B; Menkes CJ
    Lancet; 1983 Mar; 1(8323):538. PubMed ID: 6131248
    [No Abstract]   [Full Text] [Related]  

  • 8. Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin.
    Shawket S; Dickerson C; Hazleman B; Brown MJ
    Br J Clin Pharmacol; 1991 Aug; 32(2):209-13. PubMed ID: 1931469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].
    Keller J; Kaltenecker A; Schricker KT; Krais T; Schönberger A; Gevatter M; Hornstein OP
    Dtsch Med Wochenschr; 1984 Sep; 109(38):1433-8. PubMed ID: 6383760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers.
    Cruz JE; Ward A; Anthony S; Chang S; Bae HB; Hermes-DeSantis ER
    Ann Pharmacother; 2016 Dec; 50(12):1060-1067. PubMed ID: 27465880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin.
    Pola P; Tondi P; Serricchio M; Favuzzi A; Gerardino L
    Angiology; 1993 Feb; 44(2):123-8. PubMed ID: 8434805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.
    Yardumian DA; Isenberg DA; Rustin M; Belcher G; Snaith ML; Dowd PM; Machin SJ
    Br J Rheumatol; 1988 Jun; 27(3):220-6. PubMed ID: 2454140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.
    McHugh NJ; Csuka M; Watson H; Belcher G; Amadi A; Ring EF; Black CM; Maddison PJ
    Ann Rheum Dis; 1988 Jan; 47(1):43-7. PubMed ID: 2449871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoprostenol in patients with Raynaud's disease.
    Fitscha P; Kaliman J; Weidinger F; Sinzinger H; O'Grady J
    Prostaglandins Leukot Essent Fatty Acids; 1988 Jul; 33(1):23-7. PubMed ID: 3141936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Digital necrosis in Raynaud's phenomenon revealing a testicular seminoma. Value of prostacyclin].
    Taillan B; Ferrari E; Castanet J; Campagni JP; Garnier G; Fuzibet JG; Benchimol D; Dujardin P
    Presse Med; 1992 Jun; 21(23):1070-1. PubMed ID: 1387938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New treatments for Raynaud's syndrome].
    Bellucci S; Kedra W; Ajzenberg N; Tobelem G; Caen J
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):103-7. PubMed ID: 3290833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raynaud's disease.
    Burns EC; Dunger DB; Dillon MJ
    Arch Dis Child; 1985 Jun; 60(6):537-41. PubMed ID: 3160308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.
    Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM
    Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.
    Martin MF; Dowd PM; Ring EF; Cooke ED; Dieppe PA; Kirby JD
    Ann Rheum Dis; 1981 Aug; 40(4):350-4. PubMed ID: 7259326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.